Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study
Victoria Hamill, Stanley Wong, Jennifer Benselin, Mel Krajden, Peter Hayes, David Mutimer, Amanda Yu, John Dillon, William Gelson, Hector Velásquez García, Alan Yeung, Philip Johnson, Stephen Barclay, Maria Alvarez, Hidenori Toyoda, Kosh Agarwal, Andrew Fraser, Sofia Bartlett, Mark Aldersley, Andrew Bathgate, Mawuena Binka, Paul Richardson, Joanne Morling, Stephen Ryder, Douglas MacDonald, Sharon Hutchinson, Eleanor Barnes, Indra Neil Guha, William Irving, Naveed Janjua, Hamish Innes
This study compared mortality rates for patients treated for hepatitis C in the era of direct acting antivirals with the general population. Mortality rates among people successfully treated for hepatitis C in the era of interferon-free, direct acting antivirals are high compared with the general population. Drug and liver related causes of death were the main drivers of excess mortality.